#PharmaInnovation #Endocrinology #CardiovascularHealth #GLP1 #Rybelsus #Semaglutide #MedicalAffairs #LifeSciences To view or add a comment, sign in FDA Approves Rybelsus for Heart Protection in High-Risk Diabetics Novo Nordisk's oral GLP-1 agonist Rybelsus has received FDA label expansion for cardiovascular risk reduction in high-risk type 2 diabetes patients, covering both primary and secondary prevention of major adverse cardiovascular events (MACE)
The procedure is painless and noninvasive
Fast&Up L-Carnitine Supplement 3000mg in Orange Flavor combo delivers clinically tested Carnipure with Garcinia Cambogia and Potassium to support fat burning, energy production, lean body goals, and better workout performance
Construction of a rat inferior vena cava stenosis-induced DVT model Rats were randomly divided into model (M, n = 20) and control (F, n = 20) groups
You should contact your GP or practice nurse if you experience: Painful, burning, or stinging sensations when urinating Increased urinary frequency or urgency that is new or unusual Blood in your urine Cloudy or foul-smelling urine Lower abdominal or pelvic pain Mild fever or general malaise Seek urgent medical attention (contact NHS 111 or attend an urgent treatment centre or A&E) if you develop: High fever (above 38C) with chills or rigors Severe pain in your back, side, or groin Persistent vomiting that prevents you from keeping down fluids or oral medicines Confusion or altered mental state Symptoms of sepsis, including rapid heartbeat, rapid breathing, or feeling extremely unwell These symptoms may indicate an upper urinary tract infection or systemic infection requiring immediate assessment and possible hospital admission
Applying gentle pressure with a clean cotton wool ball immediately after injection can help reduce bleeding and bruising, though vigorous rubbing should be avoided as this may increase irritation and affect medication absorption
